Variant Identification in BARD1 , PRDM9 , RCC1 , and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools
- 1 March 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 15 (3) , 151-160
Abstract
Several ovarian cancer susceptibility genes have been discovered, but more are likely to exist. In this study, we aimed to analyze knowledge-based selected genes, that is, BARD1, PRDM9, RCC1, and RECQL, in which pathogenic germline variants have been reported in patients with breast and/or ovarian cancer. As deep sequencing of DNA samples remains costly, targeted next-generation sequencing of DNA pools was utilized to screen the exons of BARD1, PRDM9, RCC1, and RECQL in approximately 400 Polish ovarian cancer cases. A total of 25 pools of 16 samples (including several duplicated samples with known variants) were sequenced on the NovaSeq6000 and analyzed with SureCall (Agilent) application. The set of variants was filtrated to exclude spurious variants, and, subsequently, the identified rare genetic variants were validated using Sanger sequencing. No pathogenic mutation was found within the analyzed cohort of patients with ovarian cancer. Validation genotyping of filtered rare silent and missense variants revealed that the majority of them were true alterations, especially those with a higher mutation quality value. The high concordance (R2 = 0.95) of population allele frequency for 44 common SNPs in the European control population (gnomAD) and our experiment confirmed the reliability of pooled sequencing. Mutations in BARD1, PRDM9, RCC1, and RECQL do not contribute substantially to the risk of ovarian cancer. Pooled DNA sequencing is a cost-effective and reliable method for the initial screening of candidate genes; however, it still requires validation of identified rare variants. Prevention Relevance: BARD1, PRDM9, RCC1, and RECQL are not high/moderate-risk ovarian cancer susceptibility genes. Pooled sequencing is a reliable and cost-effective method to detect rare variants in candidate genes.Keywords
All Related Versions
Funding Information
- Polish National Science Centre (NCN 2015/17/B/NZ2/01182, 2016/22/A/NZ2/00184)
This publication has 48 references indexed in Scilit:
- Rare allelic forms of PRDM9 associated with childhood leukemogenesisGenome Research, 2012
- Predicting the Functional Effect of Amino Acid Substitutions and IndelsPLOS ONE, 2012
- Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov ModelsHuman Mutation, 2012
- SIFT web server: predicting effects of amino acid substitutions on proteinsNucleic Acids Research, 2012
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel diseaseNature Genetics, 2011
- High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiencyNature Genetics, 2010
- PRDM9 variation strongly influences recombination hot-spot activity and meiotic instability in humansNature Genetics, 2010
- Functional annotations improve the predictive score of human disease-related mutations in proteinsHuman Mutation, 2009
- Rare Variants of IFIH1 , a Gene Implicated in Antiviral Responses, Protect Against Type 1 DiabetesScience, 2009